The ocular manifestations in IBD screening (OMIS) questionnaire: pilot study on detection of ocular involvement in inflammatory bowel diseases.
Biologic drugs
Inflammatory bowel disease
Ocular extraintestinal manifestation
Questionnaire
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
23
02
2020
accepted:
19
05
2020
pubmed:
9
6
2020
medline:
22
6
2021
entrez:
9
6
2020
Statut:
ppublish
Résumé
To assess the usefulness of a dedicated questionnaire for patients with inflammatory bowel diseases (IBD) treated with biological drugs for the detection of ocular extraintestinal manifestations (EIMs). IBD can cause extraintestinal symptoms including ocular complaints which are frequently ignored and may be associated with significant morbidity, including blindness. We developed a questionnaire, named Ocular Manifestations in IBD Screening (OMIS) questionnaire, after agreement between gastroenterologists and ophthalmologists. The questionnaire was administered by a non-ophthalmologist physician to 96 IBD patients treated with biological drugs. 35 patients (36.5%) were selected for the ophthalmologic examination on the basis of a positive screening test. Ocular EIMs were detected in 29 of 35 patients (83%). A specific questionnaire can be useful for non-ophthalmologist physicians in a real world setting in order to select patients to be addressed to an ophthalmological visit, creating an integrated multidisciplinary clinical team, to improve management of IBD in order to prevent disability and guarantee quality of life.
Identifiants
pubmed: 32507951
doi: 10.1007/s10792-020-01437-x
pii: 10.1007/s10792-020-01437-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2569-2576Références
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G (2015) Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 21(8):1982–1992
doi: 10.1097/MIB.0000000000000392
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G et al (2005) Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 11(46):7227–7236
doi: 10.3748/wjg.v11.i46.7227
Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106(1):110–119
doi: 10.1038/ajg.2010.343
Zippi M, Corrado C, Pica R, Avallone EV, Cassieri C, De Nitto D et al (2014) Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol 20(46):17463–17467
doi: 10.3748/wjg.v20.i46.17463
Troncoso LL, Biancardi AL, De Moraes HV, Zaltman C (2017) Ophthalmic manifestations in patients with inflammatory bowel disease: a review. World J Gastroenterol 23(32):5836–5848
doi: 10.3748/wjg.v23.i32.5836
Uchiyama E, Papaliodis GN, Lobo A, Sobrin L (2015) Side-effects of anti-inflammatory therapy in uveitis. Semin Ophthalmol 29(5–6):456–467
Cordero-Coma M, Sobrin L (2015) Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol 60(6):575–589
doi: 10.1016/j.survophthal.2015.06.004
Mady R, Grover W, Butrus S (2015) Ocular complications of inflammatory bowel disease. Sci World J 2015:438402
doi: 10.1155/2015/438402
Pasadhika S, Rosenbaum JT (2014) Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics 15(8):67–81
Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F et al (2017) Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study. Inflamm Bowel Dis 23(7):1174–1181
doi: 10.1097/MIB.0000000000001109
Maaser C, Sturm A, Vavrika SR, Kucharzik T, Fiorino G, Annese V et al (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144–164
doi: 10.1093/ecco-jcc/jjy113
Di Carlo M, Luchetti MM, Benfaremo D, Di Donato E, Mosca P, Maltoni S et al (2018) The DETection of Arthritis in Inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis. Clin Rheumatol 37(4):1037–1044
doi: 10.1007/s10067-017-3937-6
Vavricka S, Scharl M, Gubler M, Rogler G (2014) Biologics for extraintestinal manifestations of IBD. Curr Drug Targets 15(11):1064–1073
doi: 10.2174/1389450115666140908125453
Chan HC, Ng SC (2017) Emerging biologics in inflammatory bowel disease. J Gastroenterol 52(2):141–150
doi: 10.1007/s00535-016-1283-0
Calvo P, Pablo L (2013) Managing IBD outside the gut: ocular manifestations. Dig Dis 31(2):229–232
doi: 10.1159/000353375
Ballonzoli L, Bourcier T (2010) Complications ophthalmologiques des immunosuppresseurs et des corticoïdes. Thérapie 65(2):115–120
pubmed: 20478243
Conway MD, Stern E, Enfield DB, Peyman GA (2018) Management of cataract in uveitis patients. Curr Opin Ophthalmol 29(1):69–74
doi: 10.1097/ICU.0000000000000438
Song P, Wang H, Theodoratou E, Chan KY, Rudan I (2018) The national and subnational prevalence of cataract and cataract blindness in China: a systematic review and meta-analysis. J Glob Health 8(1):010804
doi: 10.7189/jogh.08.010804
Foster CS, Vitale AT (2013) Diagnosis and treatment of uveitis, 2nd edn. Jaypee Brothers Medical Publishers, New Delhi, pp 803–805
Cloché V, Buisson A, Tréchot F, Batta B, Locatelli A, Favel C et al (2013) Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease. Dig Liver Dis 45(3):195–199
doi: 10.1016/j.dld.2012.10.013
Felekis T, Katsanos K, Kitsanou M, Trakos N, Theopistos V, Christodoulou D et al (2009) Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm Bowel Dis 15(1):29–34
doi: 10.1002/ibd.20584
Palm Ø, Moum B, Gran JT (2002) Estimation of Sjogren’s syndrome among IBD patients: a six year post-diagnostic prevalence study. Scand J Rheumatol 31(3):140–145
doi: 10.1080/rhe.31.3.140.145
Queiro R, Rodríguez-Caminero S, Riestra S, De Francisco R, Pérez-Martìnez I, Ballina J (2018) Performance of two screening questionnaires for inflammatory arthritis in patients with inflammatory bowel disease. Biomed Res Int 2018:8618703
doi: 10.1155/2018/8618703